Insmed’s BRINSUPRI Approved by European Commission

Insmed ( (INSM) ) has provided an announcement.

On November 18, 2025, Insmed announced that the European Commission approved BRINSUPRI (brensocatib 25 mg tablets) for treating non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older with two or more exacerbations in the past year. This approval marks a significant milestone as BRINSUPRI becomes the first and only approved treatment for NCFB in the EU, potentially reshaping the treatment landscape for this debilitating disease. The decision was based on data from the Phase 3 ASPEN and Phase 2 WILLOW studies, which demonstrated a reduction in exacerbations and a slower decline in lung function. Insmed plans to engage with EU authorities to secure access for eligible patients starting in early 2026.

The most recent analyst rating on (INSM) stock is a Buy with a $214.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.

Spark’s Take on INSM Stock

According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.

Insmed’s stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flow issues. While technical analysis shows strong momentum, valuation concerns due to a negative P/E ratio and lack of dividends weigh heavily. The positive sentiment from the earnings call is not factored into the overall score due to its exclusion from the weighted calculation.

To see Spark’s full report on INSM stock, click here.

More about Insmed

Insmed Incorporated is a global biopharmaceutical company focused on delivering first- and best-in-class therapies to transform the lives of patients with serious diseases. The company is dedicated to addressing unmet medical needs, particularly in underserved patient communities.

Average Trading Volume: 2,161,435

Technical Sentiment Signal: Buy

Current Market Cap: $41.21B

For an in-depth examination of INSM stock, go to TipRanks’ Overview page.